Aiping Zeng

发表

Pretreatment plasma d-dimer levels as an independent prognostic factor for overall survival among patients with advanced non-small-cell lung cancer

Jianbo He, Qianfei Liu, Ruiling Ning, 2020, The Journal of international medical research.

Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study

W. Feng, H. Pan, Xiaorong Dong, 2021, EClinicalMedicine.

Clinical Analysis of Medical IoT and Acute Cerebral Infarction Based on Image Recognition

Yiju Xie, Aiping Zeng, Shengxiang Yang, 2022, Mobile Information Systems.

Ef ﬁ cacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial

Lei Wang, Xueqin Chen, Wei Li, 2022 .

PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study

Wei Jiang, Jianbo He, Wenhua Zhao, 2022, Frontiers in Immunology.

Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study

W. Wang, Jinsheng Hong, Liangfang Shen, 2022, The Lancet regional health. Western Pacific.

Ef ﬁ cacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase 2 study

R. Guo, Jiong Cai, S. Qiu, 2022 .

Prognostic Value of Pretreatment Albumin-to-Alkaline Phosphatase Ratio in Extensive-Disease Small-Cell Lung Cancer: A Retrospective Cohort Study

Wei Jiang, Aiping Zeng, Shaozhang Zhou, 2020, Cancer management and research.

CMAR_A_247967 2015..2024

Wei Jiang, Aiping Zeng, Shaozhang Zhou, 2020 .

The role of the HGF/c-Met signaling pathway in crizotinib-induced apoptosis in lung cancer with c-Met amplification

Ruiling Ning, Aiping Zeng, Shaozhang Zhou, 2017, Oncology and Translational Medicine.

Efficacy and safety of SH-1028 in patients with EGFR T790M positive non-small-cell lung cancer: a multicenter, single-arm, open-label, phase 2 trial.

Xueqin Chen, L. Xing, S. Ren, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib.

D. Carbone, Yangming Ou, Likun Chen, 2019, Lung Cancer.

Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial

Huiping Li, He-long Zhang, Runxiang Yang, 2023, BioDrugs.

RET fusion in first/third-generation EGFR-TKIs resistance in advanced non-small cell lung cancer.

Jun Zhao, X. Xia, Aiping Zeng, 2019, Journal of Clinical Oncology.

Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines

Aiping Zeng, Shaozhang Zhou, Qitao Yu, 2018, Anti-cancer drugs.